NCT07380737 Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study
| NCT ID | NCT07380737 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Condition | Parkinson's Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-12-29 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-12-29 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot study designed to assess the feasibility, adherence, and preliminary effects of a 6-week home-based gait training intervention using the Walking Tall mobile app in individuals with Parkinson's disease. The app delivers rhythmic auditory cues and motivational verbal prompts to promote gait improvements. Primary outcomes include daily walking duration and step count measured via wearable sensors; secondary outcomes include gait speed, balance, self-reported confidence, and usability.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis of idiopathic Parkinson's disease (MDS criteria); * Hoehn \& Yahr stage II-III (ON-medication state); * Able to walk independently for ≥5 minutes; * Stable medication for ≥1 month; * Currently enrolled in a rehab program at Ezra LeMarpe; * Able to provide written informed consent; Exclusion Criteria: * Musculoskeletal, neurological, or visual/hearing impairments affecting gait; * Cognitive impairments or severe behavioral symptoms; * History of stroke, severe TBI, or brain tumor; * Cardiovascular contraindications; * Inability to use a smartphone; * Participation in other concurrent intervention studies.
Contact & Investigator
Tatyana Gurevich, Prof
PRINCIPAL INVESTIGATOR
Head of the Movement Disorders Unit at Ichilov Hospital
Frequently Asked Questions
Who can join the NCT07380737 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Parkinson's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07380737 currently recruiting?
Yes, NCT07380737 is actively recruiting participants. Contact the research team at marinab@tlvmc.gov.il for enrollment information.
Where is the NCT07380737 trial being conducted?
This trial is being conducted at Tel Aviv, Israel.
Who is sponsoring the NCT07380737 clinical trial?
NCT07380737 is sponsored by Tel-Aviv Sourasky Medical Center. The principal investigator is Tatyana Gurevich, Prof at Head of the Movement Disorders Unit at Ichilov Hospital. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.